Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E16.40 EPS (ttm)5.65 Insider Own0.10% Shs Outstand1.48B Perf Week-0.38%
Market Cap164.95B Forward P/E7.97 EPS next Y11.63 Insider Trans-1.97% Shs Float1.76B Perf Month10.64%
Income8.39B PEG1.60 EPS next Q2.17 Inst Own63.10% Short Float4.84% Perf Quarter8.12%
Sales34.06B P/S4.84 EPS this Y42.30% Inst Trans1.39% Short Ratio6.35 Perf Half Y5.64%
Book/sh-5.01 P/B- EPS next Y13.06% ROA11.30% Target Price93.69 Perf Year19.40%
Cash/sh- P/C- EPS next 5Y10.25% ROE-103.70% 52W Range62.55 - 97.86 Perf YTD4.66%
Dividend4.72 P/FCF23.53 EPS past 5Y36.80% ROI21.20% 52W High-5.30% Beta0.79
Dividend %5.09% Quick Ratio3.00 Sales past 5Y10.80% Gross Margin77.10% 52W Low48.15% ATR2.69
Employees30000 Current Ratio3.10 Sales Q/Q10.10% Oper. Margin39.90% RSI (14)66.19 Volatility2.55% 3.23%
OptionableYes Debt/Eq- EPS Q/Q22.50% Profit Margin24.60% Rel Volume0.96 Prev Close90.03
ShortableYes LT Debt/Eq- EarningsMay 01 BMO Payout77.50% Avg Volume13.42M Price92.67
Recom2.30 SMA205.10% SMA5013.68% SMA20013.75% Volume12,859,367 Change2.93%
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-11-20Resumed Morgan Stanley Overweight $95
Apr-20-20Upgrade RBC Capital Mkts Sector Perform → Outperform $79 → $93
Mar-23-20Downgrade Societe Generale Buy → Hold
Feb-27-20Initiated Barclays Equal Weight $97
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Sector Perform $86
Dec-26-19Reiterated Cowen Outperform $90 → $98
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Oct-22-18Reiterated SunTrust Buy $157 → $135
May-29-20 06:47PM  Gilead Continues to Build Cancer Franchise GuruFocus.com
04:13PM  FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women PR Newswire
May-28-20 09:10AM  Ironwood to Halt MD-7246 Development After Study Failure Zacks
08:12AM  Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Zacks
May-27-20 05:48PM  Top 1st-Quarter Buys of Steven Cohen's Firm GuruFocus.com
12:16PM  Point72 Asset Management Buys Micron Technology, Baxter GuruFocus.com
10:50AM  Top Ranked Income Stocks to Buy for May 27th Zacks
09:36AM  How Trading Your Own Retirement Can Fleece Your Financial Future - May 27, 2020 Zacks
08:51AM  AbbVie, Ironwood to discontinue experimental IBS drug MarketWatch
08:30AM  AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio PR Newswire
May-26-20 11:28AM  Hedge Funds Have Never Been This Bullish On AbbVie Inc (ABBV) Insider Monkey
08:00AM  AbbVie Wrapped Its $63 Billion Allergan Buyout Is AbbVie Stock A Buy? Investor's Business Daily
May-25-20 11:45AM  This is Why AbbVie (ABBV) is a Great Dividend Stock Zacks
May-24-20 07:11AM  Better Buy: AbbVie vs. Merck Motley Fool
May-22-20 04:26PM  Coronavirus latest: Friday, May 22 Yahoo Finance Video
01:36PM  Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple Zacks
12:10PM  Allergan Finance, LLC -- Moody's withdraws Allergan's ratings Moody's
11:37AM  Better Buy: AbbVie vs. Eli Lilly Motley Fool
10:41AM  Top Ranked Income Stocks to Buy for May 22nd Zacks
08:50AM  Is AbbVie (ABBV) Stock a Solid Choice Right Now? Zacks
01:05AM  Edited Transcript of ABBV earnings conference call or presentation 1-May-20 1:00pm GMT Thomson Reuters StreetEvents
May-21-20 03:48PM  Fmr. CDC Official: 'were not cutting any corners' on COVID-19 vaccine development Yahoo Finance Video
09:56AM  Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat Zacks
May-20-20 09:23AM  Here are the hot dogs that hedge funds have used to outperform this year MarketWatch
08:59AM  AbbVie, Interactive, Inphi, Chegg and ServiceNow highlighted as Zacks Bull and Bear of the Day Zacks
08:59AM  JPMorgan: 2 Stocks to Snap Up Now (And 1 to Avoid) TipRanks
08:43AM  Top Ranked Value Stocks to Buy for May 20th Zacks
07:35AM  3 Value Stocks That Could Thrive in a Post-Pandemic World Zacks
06:45AM  Bull of the Day: AbbVie (ABBV) Zacks
06:42AM  J&J to Stop Sale of Talc-Based Baby Powder in North America Zacks
May-19-20 12:00PM  AbbVie (ABBV) Upgraded to Strong Buy: Here's What You Should Know Zacks
11:30AM  Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year? Zacks
07:51AM  New Strong Buy Stocks For May 19th Zacks
May-18-20 11:50AM  Is AbbVie (ABBV) a Great Value Stock Right Now? Zacks
09:55AM  The Zacks Analyst Blog Highlights: JPMorgan Chase, AbbVie, Royal Dutch Shell, Gilead Sciences and Anthem Zacks
May-15-20 01:21PM  Top Stock Reports for JPMorgan, AbbVie & Royal Dutch Shell Zacks
10:45AM  Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY Zacks
08:30AM  AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio PR Newswire
May-14-20 08:00AM  AbbVie to Present at the UBS Virtual Healthcare Conference PR Newswire
06:27AM  Is Now a Good Time To Buy Neurocrine Biosciences? Motley Fool
May-13-20 03:45PM  Dow Jones Slides 1,171 Points In 3 Days After Fed Chair Speech Sharpens Recession Fear Investor's Business Daily
12:03PM  AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst Benzinga
11:06AM  2 Value Stocks That Will Make You Richer in May Motley Fool
11:00AM  3 Stocks That Could Help You Send Your Kids to College Motley Fool
08:00AM  AbbVie Announces Final Results of Exchange Offers for Allergan Notes PR Newswire
07:02AM  Is AbbVie a Buy Now That the Allergan Deal Is Done? Motley Fool
May-12-20 06:45PM  Wall Street Ends in the Red on Tuesday GuruFocus.com
02:05PM  The Dow Cant Hang On and REITs Are Getting Crushed Barrons.com
12:59PM  AbbVie Is a Buy as Allergan Deal Closes - A Look at the Charts TheStreet.com
12:10PM  FORM 8.3 - ABBVIE INC - Amendment Business Wire
11:04AM  AbbVie Stock Has 15% Upside With Merger Done, J.P. Morgan Analyst Says Barrons.com
08:44AM  AbbVie Gets Favorable Analyst Reviews After Allergan Merger TheStreet.com
06:23AM  AbbVie Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next Simply Wall St.
May-11-20 05:41PM  The Dow Slipped 109 Points Because Reopened Economies Arent Business as Usual Barrons.com
12:59PM  AbbVie Stock Is Unsustainably Cheap After Allergan Acquisition Barrons.com
10:43AM  The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance TheStreet.com
08:05AM  Form 8.3 - AbbVie Inc. Business Wire
06:38AM  Form 8.3 - ABBVIE INC Business Wire
May-10-20 07:55AM  AbbVie Stock: Love It or Leave It? Motley Fool
May-09-20 08:00AM  3 Best Healthcare Stocks to Buy in May Motley Fool
May-08-20 04:54PM  AbbVie closes acquisition of Allergan MarketWatch
04:15PM  AbbVie Completes Transformative Acquisition of Allergan PR Newswire
11:45AM  Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice Zacks
09:53AM  Signs That Your Trading Will Ruin Your Retirement - May 08, 2020 Zacks
07:55AM  Form 8.3 - AbbVie Inc. Business Wire
05:17AM  Form 8.3 - ABBVIE INC Business Wire
May-07-20 09:50PM  AbbVie Remains a Top Large-Cap Pick, Says Mizuho SmarterAnalyst
08:21AM  Form 8.3 - AbbVie Inc. Business Wire
05:43AM  Form 8.3 - Abbvie Inc Business Wire
May-06-20 07:23PM  DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600 PR Newswire
02:53PM  3 Dividend Stocks Perfect for Retirees Motley Fool
11:13AM  The Charts of AbbVie Can Reach New Heights TheStreet.com
10:51AM  Form 8.3 - Abbvie Inc - Amendment Business Wire
10:23AM  AbbVie's Pending Acquisition of Allergan Earns FTC Approval Motley Fool
08:42AM  The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle Benzinga
08:35AM  US regulator clears AbbVies $63bn deal for Allergan Financial Times
08:21AM  Form 8.3 - Abbvie Inc Business Wire
08:07AM  Form 8.3 - AbbVie Inc. Business Wire
03:38AM  AbbVie Scores US Antitrust Approval for $63B Allergan Deal SmarterAnalyst
May-05-20 10:34PM  AbbVie wins U.S. antitrust approval to buy Allergan Reuters
08:43PM  AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes and Expects No Further Extensions of Expiration Date PR Newswire
06:14PM  Abbvie's deal for Allergan clears U.S. antitrust hurdle MarketWatch
05:51PM  AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan PR Newswire
08:08AM  Form 8.3 - AbbVie Inc. Business Wire
07:01AM  AbbVie Receives Health Canada Approval for the Combination of VENCLEXTA® (venetoclax) with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia CNW Group
06:59AM  Form 8.3 - ABBVIE INC Business Wire
May-04-20 02:29PM  Stock Market Today With Jim Cramer: Time to Sell Stocks? TheStreet.com
07:57AM  Form 8.3 - ABBVIE PLC AMENDMENT Business Wire
07:47AM  Form 8.3 - ABBVIE INC - Amendment Business Wire
07:40AM  Form 8.3 - AbbVie Inc. Business Wire
07:23AM  Form 8.3 - Abbvie Plc - Amendment Business Wire
07:22AM  Drugmaker AbbVie Reiterates 2020 Guidance, Beats Quarterly Sales TipRanks
05:43AM  Form 8.3 - ABBVIE INC Business Wire
02:00AM  Form 8.3 - AbbVie Inc. Business Wire
May-03-20 09:21PM  Top Marijuana Stocks That Pay Dividends Investopedia
May-02-20 07:31AM  The 3 Most Important Things to Know About AbbVie's Q1 Update Motley Fool
May-01-20 05:55PM  AbbVie Beats 1st-Quarter Estimates, Keeps 2020 Guidance GuruFocus.com
04:18PM  AbbVie's Humira Puts Up Strong Showing, But Allergan Questions Linger Investor's Business Daily
02:30PM  AbbVie Inc (ABBV) Q1 2020 Earnings Call Transcript Motley Fool
11:18AM  AbbVie Posts First-Quarter Earnings Beat on Strong Humira Sales TheStreet.com
AbbVie Inc., a research-based biopharmaceutical company, develops and markets pharmaceutical products in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a biologic therapy administered as an injection for autoimmune and intestinal diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the treatment of patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stewart Jeffrey RyanSVP, US Commercial OperationsMay 12Sale90.0023,0242,072,21152,760May 12 05:44 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMay 05Sale85.0019,4451,652,8250May 07 05:01 PM
Durkin Brian LVP, ControllerMar 30Buy69.0075051,75016,844Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 20Buy67.5080054,00016,094Mar 20 04:56 PM
Durkin Brian LVP, ControllerMar 18Buy68.182,200150,00515,294Mar 20 04:56 PM
RAPP EDWARD JDirectorMar 03Buy87.872,875252,6172,875Mar 04 05:14 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerSep 27Sale75.0215,5151,163,8730Oct 01 05:52 PM
Schumacher Laura JVice ChairmanSep 16Buy70.4225,0001,760,523164,838Sep 18 04:25 PM
Donoghoe NicholasSVP, Enterprise InnovationAug 29Buy66.197,525498,05713,090Aug 30 04:08 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsAug 16Buy64.4415,5521,002,16965,304Aug 20 04:16 PM
AUSTIN ROXANNE SDirectorAug 01Buy65.6625,0001,641,400117,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 31Buy66.0230,0001,980,69092,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 30Buy66.3510,000663,50062,114Jul 31 04:46 PM
Gosebruch Henry OEVP, Chief Strategy OfficerJul 29Buy67.2830,0002,018,38575,763Jul 31 04:46 PM
AUSTIN ROXANNE SDirectorJun 26Buy67.5011,500776,25052,114Jun 28 04:47 PM
CHASE WILLIAM JEVP, Finance & AdministrationJun 26Buy67.3030,4002,045,920169,552Jun 28 04:47 PM
RAPP EDWARD JDirectorJun 26Buy67.307,500504,75030,662Jun 28 04:48 PM